Thalidomide in patients with multiple myeloma and renal failure [6]

British Journal of Haematology

Volumn 125, Issue 1, 2004, Pages 96-97

  Fakhouri, Fadi ^a   Guerraoui, Houda ^a   Presne, Claire ^b   Peltier, Julie ^a   Delarue, Richard ^a   Muret, Patrice ^c   Knebelmann, Bertrand ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Multiple myeloma; Pharmacokinetics; Renal failure; Thalidomide

Indexed keywords

STEROID; THALIDOMIDE;

ADULT; AGED; CANCER RECURRENCE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; LETTER; MALE; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; FEMALE; HUMANS; HYPERKALEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 1842610155     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.04875.x     Document Type: Letter

References (5)

1. Eriksson, T., Bjorkman, S., Fyge, A. & Ekberg, H. (1992) Determination of thalidomide in plasma and blood by high-performance liquid chromatography: avoiding hydrolytic degradation. Journal of Chromatography, 582, 211-216.
2. Harris, E., Behrens, J., Samson, D., Rahemtulla, A., Russell, N.H. & Byrne, J.L. (2003) Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. British Journal of Haematology, 122, 160-161.
3. Kumar, S., Gertz, M.A., Dispenzieri, A., Lacy, M.Q., Geyer, S.M., Iturria, N.L., Fonseca, R., Hayman, S.R., Lust, J.A., Kyle, R.A., Greipp, P.R., Witzig, T.E. & Rajkumar, S.V. (2003) Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clinic Proceedings, 78, 34-39.
4. Kyle, R.A., Gertz, M.A., Witzig, T.E., Lust, J.A., Lacy, M.Q., Dispenzieri, A., Fonseca, R., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.E., Therneau, T.M. & Greipp, P.R. (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings, 78, 21-33.
5. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. & Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. The New England Journal of Medicine, 341, 1565-1571.